Rekvina Laboratories Fair Value
Rekvina Laboratories (VINRKLB) average fair value is ₹6.23 across 1 valuation models — Price-to-Sales Valuation, vs a current market price of ₹33.35 (-81.32%), fair value range ₹6.23–₹6.23.
Fair Value Analysis Export
VINRKLB Fair Value vs Current Price — Valuation Summary
VINRKLB average fair value, fair value range, price gap and valuation status across 1 models: Price-to-Sales Valuation. Check VINRKLB market cap trends to track the company's total market size over time.
Price-to-Sales Valuation
VINRKLB Fair Value Analysis — Data Sources & Coverage
Rekvina Laboratories financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. For live price and a broader fundamental view, visit VINRKLB screener.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
VINRKLB vs Healthcare Sector Peers — P/E, P/B & Market Cap
Rekvina Laboratories P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Jeena Sikho Lifecare | JSLL | 33.24 | 15.78 | ₹7,371 |
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Sat Kartar Life | SATKARTAR | 13.44 | 3.4 | ₹226 |
| KRM Ayurveda | KRMAYURVED | - | 4.56 | ₹545 |
| Emcure Pharmaceuticals | EMCURE | 37.24 | 7.08 | ₹34,821 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.